ANWA Stock Chart & Stats
€0.98
€0.04(4.28%)
At close: 4:00 PM EDT
€0.98
€0.04(4.28%)
Day’s Range― - ―
52-Week Range€0.49 - €2.08
Previous CloseN/A
Volume0.00
Average Volume (3M)777.00
Market Cap
€7.09M
Enterprise Value-€1.44
Total Cash (Recent Filing)€9.99M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Aug 28, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding8,071,202
10 Day Avg. Volume0
30 Day Avg. Volume777
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€5.62M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Capital StructureA minimal debt-to-equity ratio provides durable financial flexibility and lowers fixed interest obligations, reducing bankruptcy risk and enabling management to allocate scarce cash toward R&D or commercialization. This conservative structure supports runway during prolonged development cycles.
High Gross MarginsSustained ~65% gross margins indicate the core bovine colostrum products and oral antibody formulations have profitable unit economics, allowing the company to cover fixed costs and reinvest marginal revenue into marketing and clinical programs as sales scale, supporting long-term margin sustainability.
Established Commercial Product Plus PipelineOwning a marketed consumer product (Travelan) alongside clinical-stage assets (IMM‑529) and a platform technology provides diversified, durable value drivers: recurring OTC sales fund operations while the pipeline offers asymmetric upside from successful clinical progress or partnering/licensing outcomes over the medium term.
Bears Say
Declining Revenue And Persistent LossesAn ongoing revenue decline combined with deeply negative net, EBIT and EBITDA margins constrains internal funding for trials and commercialization. Persistent losses can force dilutive capital raises or partnership dependence, weakening shareholder value and limiting strategic optionality over months to years.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow erode cash reserves and shorten runway for clinical programs and commercial expansion. Deteriorating FCF growth increases likelihood of external financing, which can delay development timelines and complicate partner negotiations, affecting long-term execution.
Very Small WorkforceA seven-person headcount limits internal capacity for scaling manufacturing, regulatory compliance, global commercial execution and complex clinical programs. Heavy reliance on external partners or contractors raises execution risk and may slow product rollouts and trial management over the medium term.
Immuron News
ANWA FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was €0.49 and its highest was €2.08 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is €7.09M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 23 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Feb 25, 2026. The company reported -€0.175 earnings per share for the quarter, missing the consensus estimate of -€0.006 by -€0.169.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,071,202 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -€0.175 in its last earnings report, missing expectations of -€0.006. Following the earnings report the stock price went down -5.042%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in DE:ANWA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.